Memantine Efficacy and Safety in Patients With Acute Mania Associated With Bipolar I Disorder: A Pilot Evaluation
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Evaluate the efficacy and tolerability of memantine (20, 30, and 40 mg/d) in the acute treatment of adults with bipolar I disorder hospitalized for mania. METHODS: This multicenter, open-label, pilot trial included adults with bipolar I disorder (manic or mixed episode, with and without psychotic features). Patients were assigned to 21 days of treatment: cohort 1, 20 mg/d (range, 20-30 mg/d); cohort 2, 30 mg/d (range, 30-40 mg/d); cohort 3, 40 mg/d (range, 30-50 mg/d). Efficacy measures included the Young Mania Rating Scale (YMRS) and the Mania Rating Scale (>or=50% reduction in total score from baseline). The change from baseline was also assessed using the Positive and Negative Syndrome Scale in patients with psychiatric symptoms, Positive and Negative Syndrome Scale-Excited Component, Clinical Global Impression Severity and Improvement scores, and Montgomery Asberg Depression Rating Scale. RESULTS: A total of 35 patients were enrolled; 33 patients received at least 1 dose of memantine and had at least 1 postbaseline assessment using YMRS. Greatest improvement occurred in cohort 1 where half of the patients responded to memantine based on YMRS and Mania Rating Scale. At day 21, a response was observed in all patient cohorts. Treatment-emergent adverse events were reported in 19 patients (54.3%). The most frequently reported adverse events (>or=4 patients) included constipation, nausea, and headache. CONCLUSIONS: The response to memantine combined with its tolerability support conducting large-sized randomized controlled trials to investigate further the use of memantine monotherapy in the treatment of mania.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 10
- Mitchell, 2004, Major advances in bipolar disorder., Med J Aust, 181, 207, 10.5694/j.1326-5377.2004.tb06238.x · DOI
- Schiffer, 2002, Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?, Mol Neurobiol, 25, 191, 10.1385/MN:25:2:191 · DOI
- Michael, 2003, Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex., Psychopharmacology (Berl), 168, 344, 10.1007/s00213-003-1440-z · DOI · Paper page
- Bown, 2003, Attenuation of N-methyl-d-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers., Neuroscience, 117, 949, 10.1016/S0306-4522(02)00743-1 · DOI
- Tsapakis, 2002, Glutamate and psychiatric disorders., Adv Psychiatr Treat, 8, 189, 10.1192/apt.8.3.189 · DOI
- Rogoz, 2002, Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats., Neuropharmacology, 42, 1024, 10.1016/S0028-3908(02)00055-2 · DOI · Paper page
- Muller-Oerlinghausen, 2002, Bipolar disorder., Lancet, 359, 241, 10.1016/S0140-6736(02)07450-0 · DOI · Paper page
- Sachs, 2003, Unmet clinical needs in bipolar disorder., J Clin Psychopharmacol, 23, S2, 10.1097/01.jcp.0000084038.22282.47 · DOI
- Keck, 2003, The management of acute mania: encouraging results from clinical trials need to be replicated in practice., Br Med J, 327, 1001, 10.1136/bmj.327.7422.1002 · DOI
- Baldessarini, 2003, Assessment of treatment response in mania: commentary and new findings., Bipolar Disord, 5, 79, 10.1034/j.1399-5618.2003.00020.x · DOI
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Metadata
- Authors
- Keck, P. E., Hsu, H.-A., Papadakis, K., & Russo, J.
- Venue
- Clinical Neuropharmacology
- Published
- 2009-07
- Volume
- 32
- Issue
- 4
- Pages
- 199-204
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2001572391
- Cited by
- 51
- References
- 0
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Memantine Efficacy and Safety in Patients With Acute Mania Associated With Bipolar I Disorder: A Pilot Evaluation. https://app.cochat.ai/papers/10.1097/wnf.0b013e318184fae2
- The paper
- Keck, P. E., Hsu, H.-A., Papadakis, K., & Russo, J. (2009). Memantine Efficacy and Safety in Patients With Acute Mania Associated With Bipolar I Disorder: A Pilot Evaluation. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0b013e318184fae2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.